Primitive neuroectodermal tumor is a malignant (cancerous) neural crest tumor.[1] It is a rare tumor, usually occurring in children and young adults under 25 years of age. The overall 5 year survival rate is about 53%.[2]
| Primitive neuroectodermal tumor | |
|---|---|
| Other names | PNET |
 | |
| Micrograph of an H&E stained section of a peripheral PNET. | |
| Specialty | Oncology |
It gets its name because the majority of the cells in the tumor are derived from neuroectoderm, but have not developed and differentiated in the way a normal neuron would, and so the cells appear "primitive". PNET belongs to the Ewing family of tumors.
Genetics
editUsing gene transfer of SV40 large T-antigen in neuronal precursor cells of rats, a brain tumor model was established. The PNETs were histologically indistinguishable from the human counterparts and have been used to identify new genes involved in human brain tumor carcinogenesis.[3] The model was used to confirm p53 as one of the genes involved in human medulloblastomas, but since only about 10% of the human tumors showed mutations in that gene, the model can be used to identify the other binding partners of SV40 Large T- antigen, other than p53.[4][additional citation(s) needed]
Diagnosis
edit
Classification
editIt is classified into two types, based on location in the body: peripheral PNET and CNS PNET.[citation needed]
Peripheral PNET
editThe peripheral PNET (pPNET) is now thought to be virtually identical to Ewing sarcoma:
"Current evidence indicates that both Ewing's sarcoma and PNET have a similar neural phenotype and, because they share an identical chromosome translocation, they should be viewed as the same tumor, differing only in their degree of neural differentiation. Tumors that demonstrate neural differentiation by light microscopy, immunohistochemistry, or electron microscopy have been traditionally labeled PNETs, and those that are undifferentiated by these analyses have been diagnosed as Ewing's sarcoma."[5]
PNET of the CNS
edit
PNET of the CNS generally refer to supratentorial PNETs.
- In the past medulloblastomas were considered PNETs; however, they are genetically, transcriptionally and clinically distinct. As such, "infratentorial" PNETs are now referred to as medulloblastoma [citation needed].
- Pineoblastomas are embryonal tumours originating in the pineal gland and are likely distinct from supratentorial PNETs.
Treatment
editThe approach to management of a CNS PNET is first to obtain detailed imaging through MRI, as well as additional scans of the patient's body (X-ray, CT, PET, even bone marrow biopsies) to look for metastasis or other associated malignancies. The tumor will then need to be biopsied to confirm the diagnosis. After the diagnosis of a CNS PNET is confirmed, management includes neoadjuvant chemotherapy and radiation (to reduce tumor size burden), complete surgical resection with confirmed negative margins, and/or additional adjuvant post-surgical chemotherapy. CNS PNET is aggressive and must be managed as so. Palliative care services should also become involved in the patient's care team when the diagnosis is made. [6]
See also
editReferences
edit- ^ "primitive neuroectodermal tumor" at Dorland's Medical Dictionary
- ^ Smoll, N. R. (2012). "Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs)". Cancer. 118 (5): 1313–1322. doi:10.1002/cncr.26387. PMID 21837678. S2CID 8490276.
- ^ Eibl RH, Kleihues P, Jat PS, Wiestler OD (March 1994). "A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen". Am. J. Pathol. 144 (3): 556–64. PMC 1887088. PMID 8129041.
- ^ Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (November 1991). "p53 mutations in nonastrocytic human brain tumors". Cancer Res. 51 (22): 6202–5. PMID 1933879.
- ^ Kumar, Vinay; Fausto, Nelso; Abbas, Abul (2004) Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. Page 1301. ISBN 0-7216-0187-1.
- ^ Honrado, Carlo P, and Augustine L Moscatello. Primitive Neuroectodermal Tumors: Background, Epidemiology, Clinical Features, Medscape, 21 Jan. 2021, emedicine.medscape.com/article/855644-overview#a7.